• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

FDA approves injection concentrate formulation for docetaxel

Article

The FDA has approved a new one-vial formulation of the chemotherapeutic agent docetaxel (Taxotere Injection Concentrate).

The FDA has approved a new one-vial formulation of the chemotherapeutic agent docetaxel (Taxotere Injection Concentrate).

The agent is anticipated to become available nationwide in the fall in both 80-mg and 20-mg dosages.

Previously, docetaxel was available in a two-vial formulation-one vial containing docetaxel concentrate and the other with the diluent. The single vial eliminates the need for the initial dilution step with the diluent. Now at 20 mg/mL concentration, it is ready to be added directly into the infusion solution.

With one-vial docetaxel, the pharmaceutical ingredients and the 1-hour intravenous infusion administration to the patient remain the same.

Docetaxel is approved by the FDA for use in treating five types of cancer, including metastatic androgen-independent prostate cancer.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.